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III. ABSTRACT: 
Background:  
Obesity is a polymorphic chronic disease that has reached epidemic 
proportions.  Bariatric surgery including sleeve gastrectomy (SG) has an 
increasingly important role in long-term management of these patients. The 
molecular mechanisms post  SG are complex and not fully understood.  
  
Aims: 
The primary study aim is to investigate the hormonal mechanisms by which SG 
effects weight loss and related health benefits by examining the association 
between SG weight loss and biochemical/hormone levels. A secondary aim was 
to assess the improvements in obesity related chronic disease states following 
SG. 
  
Methods: 
  We conducted a prospective cohort study of obese patients undergoing SG 
and 2:1 age and sex matched non obese controls undergoing non- bariatric 
procedures during the study period from a single bariatric surgeon in Sydney. 
Height, weight, body mass index (BMI) and percentage excess body weight 
(%EBW) were determined for each subject at baseline, 3 and 6 months post  SG. 
  Plasma samples were obtained and key biochemical markers measured (NEFA 
(non-essential fatty acids), C-peptide, Ghrelin, GIP (Gastric Inhibitory Peptide), 
Glucagon Like Peptide -1 (GLP-1), insulin, resistin, visfatin, glucagon, leptin, 
Plasminogen Activator Inhibitor-1 (PAI-1)). Comparisons of baseline levels 
between obese and non obese subjects; and pre and post surgery levels and 
clinical factors in the SG cohort at 0, 3, 6 months post  SG were performed using 
unpaired and paired t-tests respectively on Graph-Pad PRISM ©  software.  
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Results: 
     16 SG patients and 32 controls were included with 3 month clinical follow up 
available for all SG subjects and 3 month biochemical follow-up available for 11 
SG subjects. In the SG cohort, the mean BMI at baseline was 43.5 +/- 1.8 kg/m2 
SEM. Males undergoing SG were heavier than females. The mean %EBW loss 
was 42.3% +/- 8.4SD at 3 months and 51.5% +/- 18.5SD at 6 months. There was a 
statistically significant incremental weight loss between 3 and 6 month time 
points from baseline, p < 0.0001 and p < 0.0009 respectively. 
     A statistically significant decrease in levels of NEFA, ghrelin, GLP-1, 
glucagon, leptin and PAI-1 was observed between baseline and 3 months post-
operative (p < 0.05).  This reduction remained statistically significant at 6 
months for NEFA and ghrelin. Due to small numbers at 6 months it is unclear if 
there are further changes in these hormone levels compared to 3 months.  
     No statistically significant difference was found for C-peptide, GIP, insulin 
or resistin between baseline and 3 months. Mean visfatin and resistin levels 
differed between subjects and controls at baseline (time 0). There was no 
difference in mean baseline BMI and %EBW lost for the patients who completed 
clinical and biochemical follow up versus those who had clinical follow-up 
alone.   
     In the SG cohort, secondary co-morbidities improved, with patients less 
dependent on oral hypoglycaemic agents for T2DM and improvements in 
hypertension, gastro-esophageal reflux disease and obstructive sleep apnea.  
 
Conclusions: 
     We demonstrate significant weight loss and hormone changes post SG 
surgery. Our research adds to the literature to identify markers that are 
associated with surgical weight loss that may provide insights into the 
endocrine mechanisms or effects of surgical weight loss.  
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IV. INTRODUCTION: 
    Substantial efforts are now focusing on combating the obesity epidemic. 
Obesity is a polymorphic chronic disease that has reached epidemic 
proportions and is now one of the most important public health issues in the 
Western world(1).  Although there is considerable evidence that body weight 
and fat mass are highly heritable traits(2), the rise in the prevalence of 
obesity has been driven by environmental factors; an abundance of calorie 
rich food and lack of physical activity(3).  Obesity is epigenetic in origin, 
with genetic and environmental components to this problem.  At a patient 
management and therapeutic level, bariatric surgery is increasingly being 
relied upon as the most effective way to enable significant and sustained 
weight loss in patients failing dietary and lifestyle measures and those who 
are severely obese. The Australian government guidelines from the 
Department of Health and Ageing support this approach.(4) 
 
With weight reduction comes a fall in cardiovascular risk profile; improved 
control of associated comorbidities such as dyslipidaemia, type II diabetes 
mellitus (T2DM), hypertension (HTN), obstructive sleep apnea (OSA), non- 
alcoholic steatohepatosis (NASH) as well as an overall drop in mortality (5, 6).  
Recent literature now indicates that there has been sufficient time latency to 
demonstrate risk reversibility for these conditions in morbidly obese cohorts 
undergoing bariatric surgery. This is in addition to a reduction in overall cancer 
risk (e.g. colon, endometrial, post-menopausal breast cancers, oesophageal 
adenocarcinoma and thyroid cancer)(7). 
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V. LITERATURE REVIEW: 
 
The three main bariatric options are, in increasing order of complexity:  
1. Laparoscopic adjustable gastric band (LAGB) surgery (Fig. 1a)  
2. Sleeve Gastrectomy (SG) (Fig. 1c)  
3. Roux en Y Gastric Bypass (RYGB)  (Fig.1b) or duodenal switch procedure  
(4, 8)   
 
SG is an operation that is increasingly preferred to gastric band as it 
demonstrates more substantial and sustained weight loss and to gastric bypass 
operations or duodenal switch which carry a higher attendant risk of morbidity 
and mortality.   
 
Figure 1a. Laparoscopic Adjustable Gastric Band Surgery: 
 
www.ucsfhealth.org 
LAGB involves placing a silicon band around the upper portion of the stomach to 
create a small gastric pouch. The tightness of the band is increased by adding fluid 
through a subcutaneous port.  Early satiety and so decreased food intake occurs. 
The main advantage is that this is a quick, safe and fully reversible procedure. 
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Disadvantages include a slower and lower weight loss than with other bariatric 
procedures (maximum 50-60% EBWL at the rate of approximately 1kg/week); the 
risk of band erosion or dislodgement, exacerbation of reflux and the need for 
adjustments over time. 
 
Figure 1b. Roux en Y Gastric Bypass Surgery: 
 
 
www.utswmedicine.org 
RYGB is the most complex of the bariatric procedures and has a multifactorial 
mechanism of action. A small gastric pouch is created followed by a proximal 
small intestinal bypass or ‘re-routing’ that confers a malabsorption syndrome, 
predominantly for fats. Weight loss is the result of volume restriction, 
malabsorption and a number of hormonal changes including decreased leptin 
and leptin resistance, increased peptide YY , GLP-1 and reduced GIP.   
Specific complications include higher perioperative mortality than LAGB, 
anastomotic leak, Vitamin B12, iron and calcium deficiencies, ‘dumping’ 
syndrome and the need for vitamin and mineral replacement lifelong. 
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Figure 1c. Sleeve Gastrectomy: 
 
 
www.lakewoodweightloss.com 
 
The hormonal/endocrinological changes that occur post LAGB and RYGB have 
been extensively studied but relatively less is known about changes post SG. 
 
To date, there is limited literature available on the underlying molecular and 
physiological mechanisms responsible for the health benefits observed with 
surgical weight loss in SG patients.  Plausible biological explanations for 
improvement in cardiovascular and cancer risk profiles consequent to a fall in 
general body adiposity  (as measured by percentage of excess body weight lost 
(%EBWL)) post-bariatric surgery include; changes in insulin/IGF-1, thyroid 
stimulating hormone (TSH), sex steroids, bile acids, gut microbiota and 
adipokines/inflammatory cytokines (9).  It is this abnormal hormonal milieu 
and increased release of adipokines and alteration in gastrointestinal and 
adipose-derived biomarkers that we wish to explore pre and post bariatric, 
specifically SG surgery.   
 
The objective of this study is to measure changes in a panel of markers (insulin, 
glucagon, ghrelin, visfatin, resistin, Glucagon Like Peptide-1 ( GLP-1) , Gastric 
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Inhibitory Peptide (GIP), leptin, C-peptide, Plasminogen Activator Inhibitor-1 
(PAI-1)) and NEFA (non essential fatty acids), to ascertain whether a change in 
the levels can be correlated to weight loss. This would help better understand 
the mechanisms by which surgically induced weight reduction and associated 
health benefits occurs.  
 
Sleeve Gastrectomy (SG) (sometimes referred to as vertical sleeve gastrectomy), 
is usually a laparoscopic procedure that involves stapled resection of 
approximately 80% of the stomach including the fundus and greater curvature. 
First described in 1998 as the initial step in a bilio-pancreatic 
diversion/duodenal switch procedure, its capacity to enable significant weight 
loss as a stand alone intervention was observed.  Additional benefits include 
gastric conduit for future endoscopic surveillance/intervention, avoidance of 
malabsorption syndromes and a low risk of future operations being required as 
well as a low overall mortality rate of 0.39% (10).  
 
SG has a multifactorial mechanism of action. A restrictive component was 
postulated as the predominant factor initially, although the finding that much 
more weight is lost following SG than LAGB despite the gastric pouch in LAGB 
being much smaller than the SG remnant stomach refutes this idea.(11)  
 
A variety of hormones have been studied for their role in weight loss and 
obesity related health conditions and a summary of those relevant to our study 
follows below. 
 
Adiponectin is an adipocyte-derived hormone that links visceral adiposity with 
many of the negative health sequelae of obesity, such as insulin resistance, 
dyslipidaemia and atherosclerosis.  It acts to increase glucose utilization by the 
liver and skeletal muscle, increase fatty acid oxidation via activation of AMP 
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kinase and acetyl-coA carboxylase.  In addition, adiponectin has anti-
inflammatory properties in cultured human endothelial cells and is inversely 
proportional to inflammatory markers in situ, such as C-peptide(12).  It exists in 
high, medium and low molecular weight forms.  The high molecular weight 
form is the most important.  Low levels are associated with ‘fat states’- that is, 
obesity, type 2 DM and NASH.  More that 20 studies to date  have shown 
increases in adiponectin after bariatric surgery, but only one included SG 
patients and to our knowledge no studies have to date examined the different 
multimers.  (13-16) 
 
Ghrelin is also known as the ‘hunger peptide’ [13].  It is an appetite stimulating 
hormone mainly produced by the oxyntic glands of the gastric body and 
fundus.  The bulk of this portion is surgically removed in sleeve gastrectomy.  
Ghrelin’s concentration is increased in starvation, binding to and activating the 
growth hormone sensing receptor in the hypothalamus, where it stimulates 
growth hormone release from the anterior pituitary; in turn promoting food 
intake, carbohydrate utilization and adiposity.  It also has a direct action on 
adipocytes to promote lipid storage.  Ghrelin levels are thought to be reduced 
post  SG.(17) 
 
Gastric inhibitory polypeptide (GIP) may also promote energy storage. 
  Ghrelin, peptide YY, gastric inhibitory polypeptide (GIP), GLP-1, 
cholecystokinin, pancreatic polypeptide and amylin are released from the 
gastrointestinal tract and pancreas in response to food ingestion.  All except 
ghrelin and peptide YY are negative feedback hormones that inhibit food intake 
(18).  There have been conflicting data in the literature concerning ghrelin levels 
post bariatric surgery.  
 
Leptin was the first fat cell (adipocyte)-derived hormone to be discovered 
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in the 1960’s.  It acts via its receptor in the hypothalamus - the region of the 
brain known to regulate appetite, food intake and body weight. It is a surrogate 
indicator of fat stores and gene mutations have been shown to result in obesity 
[16].  The protein product leptin, is an anorexigenic agent. That is, it acts to 
reduce food intake and increase energy expenditure. [13,17] 
Circulating leptin levels are lower than expected for body weight following 
SG.(17) 
 
Resistin is an adipokine, found to induce insulin resistance in mice.  Increased 
levels are correlated with increased fat mass.  It is found in white fat which is 
known to play a significant role in the pathogenesis of insulin resistance and to 
promote the chronic inflammatory state that is conferred by obesity. (19) 
 
Visfatin, is an adipokine involved in inflammatory phenomena, atherosclerosis, 
and possibly in insulin secretion. It is an established marker of visceral 
adiposity with direct correlation to the risk of developing type 2 diabetes and 
the metabolic syndrome. (20) 
 
 Other metabolic parameters: 
C-peptide  is the connecting peptide in the proinsulin molecule and is co-
secreted with insulin and can be used to assess insulin secretion. 
 
NEFAs are free fatty acids released by adipocytes in response to lipolytic stimuli 
like weight loss. 
 
Co-morbidities and the effect of obesity surgery: 
Recent studies have reinforced the credence that bariatric surgery is a beneficial 
treatment option for the improvement of type 2 diabetes mellitus (T2DM) in 
obese individuals.  Schauer et al. compared the effects of bariatric surgery (Roux-
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en-Y gastric bypass or SG) in combination with medical therapy to medical 
therapy alone on glycaemic control (measured by glycosylated haemoglobin) in 
obese patients with advanced T2DM(21). Glycaemic control was improved in 
all three study groups, however, the most marked reduction was observed for 
patients who underwent gastric bypass, followed by SG (42% and 37% of 
patients achieving glycosylated haemoglobin of < 6%, respectively, versus 12% 
for medical therapy alone group. P<0.05 for all comparisons ). The authors 
postulated that this improvement in glycaemic control observed for patients 
who underwent surgery is due to a rise in insulin sensitivity, which may in turn 
be linked to a reduction in chronic inflammation. Similarly, Mingrone and 
colleagues found that remission of T2DM (defined as a glycosylated 
haemoglobin level of < 6.5%, without concomitant pharmacologic therapy) 
occurred in 75% and 95% of severely obese patients who underwent gastric 
bypass or bilio-pancreatic diversion respectively, with no remission observed 
for patients who received standard medical therapy  (P< 0.001) (22). In keeping 
with previous reports, it was shown that there was no correlation between the 
degree of weight loss and normalisation of glycaemia, suggesting that bariatric 
surgery may exert its positive effect on T2DM via mechanisms that are 
independent of weight.   A recent analysis of the Swedish Obese Subjects (SOS) 
study results demonstrates that bariatric surgery exerts a preventative effect, 
with regard to the incidence of T2DM (23). This longitudinal study, carried out 
over 15 years on an obese, non-diabetic patient cohort showed that T2DM 
developed in 392 patients who received regular treatment for obesity, versus 
110 patients who underwent bariatric surgery.  Interestingly, it was found that 
baseline BMI is not predictive of a beneficial outcome of bariatric surgery, in 
terms of the onset of type 2 diabetes. The results of this study again suggest that 
bariatric surgery results in sustained weight loss over time, however whether it 
is this weight loss directly, or other factors influencing T2DM progression, such 
as incretin and other adipokine levels are as yet not known. 
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VI. AIMS: 
The primary research questions we pose are:  
 
What changes occur in the circulating levels of peripheral hormones involved in the 
homeostatic regulation of body weight pre versus post sleeve gastrectomy (SG)?   
 
Does amount of weight lost correlate to the change in hormone/biomarker levels? 
 
The study aims to find if there exists a difference in circulating levels of 
peripheral hormones in: 
i) obese patients pre-operatively compared to normal controls 
ii) in obese patients pre and post operatively (three and six months after 
bariatric intervention). 
 
These analyses will allow us to explore whether these hormones could be 
responsible for conferring a physiochemical component to weight loss and/or 
the health benefits associated with weight loss in obese patients. 
 
Biomarkers studied were: NEFA, C-peptide, ghrelin, GIP, GLP-1, glucagon, 
insulin, leptin, PAI-1, resistin and visfatin. 
 
Primary outcomes were weight loss and change in biochemical profiles as 
measured by bioassay. 
 
 Outcome measures were percentage of excess body weight lost and 
biochemical levels of markers involved in obesity (mM for NEFA and pg/ml for 
all others).  This  involved the primary endpoint of change in hormone levels 
related to obesity as listed above. Other endpoints were percentage of excess 
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body weight lost (%EBWL). Where ideal body weight equates to a BMI=25 and 
excess body weight is calculated as actual minus ideal body weight in 
kilograms.  Surrogate endpoints were indicators of an improvement in health 
outcomes post SG, i.e improvement and reversal of clinical conditions related to 
obesity; diabetes (by HbA1C, need for insulin or oral hypoglycaemic 
medications); arthritis and obstructive sleep apnoea.  The measure of effect was 
studied by comparing the groups before and after surgery; % EBWL, 
percentage change of hormone levels and comparing the SG group to controls 
for hormone profile mean differences.  These endpoints were measured at 
timing intervals of zero, three and six months. 
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VII. METHODS: 
 
Study design: 
This is a prospective cohort study performed over a six month duration as a 
pilot study to inform the design of a larger study to investigate the hormones 
involved in the homeostatic regulation of body weight.  
 
Setting (Site) and participant selection with controls: 
Patients presenting to a single upper gastrointestinal and bariatric surgeon  
(RVL) for weight loss surgery were assessed for eligibility.  Eligibility criteria 
were: Age 18-75 years old, having exhausted non-surgical options for weight 
loss, body mass-index (BMI) greater than 30.  Persons with untreated 
malignancy or clinically significant illness precluding general anaesthesia and 
those taking medications known to affect body weight were excluded.   
 
Included patients were voluntary participants who had decided in consultation 
with their primary physician and treating surgeon that SG was their best 
surgical option.  
 
Patients were recruited who had an operative admission date between April 1st 
and June 30th, 2013. Informed written consent was obtained from all and stored 
securely in the research office.  Withdrawal from the study at any time was 
possible at the request of the patient.  
 
Surgery was performed at two private hospitals (MUH and SVPH, Sydney) 
after institutional Ethics Board Approval (bariatric surgery not being covered 
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under Medicare provision of services at public hospitals in Australia except in 
special circumstances). 
 
Ethical approval: 
Collection of patient data at SVPH/SVC was undertaken as part of a larger 
multi-institutional obesity study (Episcope). SVH Ethical Board approval was 
granted for this. Patients were educated on the goals of the study and nature of 
the blood samples taken; also that samples would be stored for future use.  
Signed consent was obtained for all and stored in a locked research office 
facility.  
 
Process for revocation of consent at any time was also made clear to each 
participant.  
 
Under the title ‘The biology, epigenetics and genetics of adipose tissue in human health 
and disease’ Macquarie University /Macquarie University Hospital Ethics Board 
granted approval for this project in accordance with NHMRC/HREC  
committee guidelines.  Similarly Notre Dame University (Sydney) ethics 
approval was obtained. 
 
Patients who had undergone non-bariatric upper gastrointestinal procedures 
(surgery or endoscopy) were used as controls. Patients were age and sex 
matched from an established gastroesophageal research specimen bank, 
ensuring they had a normal BMI (18-25), no known malignancy and were not 
diabetic.  This was performed with a 2:1 (control:case) ratio.  
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Bias: 
     This was a cohort study with 2:1 control to case ratio. Controls were age and 
sex matched to help reduce the risk of selection bias in our assessment of the 
effect of obesity on baseline hormone levels. 
     All blood samples used for the extraction of biochemical analytes in the 
hormonal assays were de-identified prior to analysis.  Hence laboratory staff 
performing the assays were blinded to the nature of the samples to reduce the 
risk of measurement bias.  Biochemical analysis was undertaken on a single 
platform to improve the reliability of the assay. 
     Anthropometric measurements were standardized by using the same scales 
and height chart to reduce the risk of random error. 
 
The statistical analyses were conducted un-blinded to case status.  
 
iii) Study Size: 
This study was designed as a pilot study to provide preliminary data to inform 
the design of a further larger study needed to provide more definitive evidence, 
therefore power calculations were not performed.  The sample size of 16 
patients reflects the number of eligible patients available for recruitment from 
one surgeon during the study period. 
 
iv) Data Collection: 
Once patients agreed to participate, a questionnaire regarding co-morbidities 
attributable to obesity was completed.  This was done in rooms at the initial 
consult and filed with the patient notes. 
 Physical examination (t = 0, 3, 6, months) was performed by one 
individual (to avoid inter-observer error). Weight (kilograms) and height 
(centimeters) were measured on the same scales which were calibrated 
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and with the same chart to measure height.  Thus the accuracy of BMI 
was ensured. 
 
 
 Some serum peripheral blood samples were kept in storage in a secure 
research freezer for each study patient and control to ensure that 
experiments could be repeated and data recalculated if necessary.  
Further analysis can also therefore occur.  This was according to the 
protocol developed by Dr. M. Swarbrick, quoted in prior accepted 
literature (14). 
 
On scheduled clinical review at three and six months, body weight, weight loss 
(%EBWL) and body mass index were again measured and recorded on the 
same chart, as was assessment of improvement or resolution of symptoms of 
obesity related co-morbidities; for example, glycaemic control (as measured by 
need for an adjusted dose of oral hypoglycaemic medication and 
HbA1C/fasting blood glucose level), hypertension (blood pressure 
>140/90mmHg; need for ongoing pharmacologic therapy), obstructive sleep 
apnoea (need for ongoing CPAP) or osteoarthritis (patient reported 
improvement in symptoms over time and exercise capacity). 
 
     Initial fasting blood samples on the day of surgery (post induction of general 
anaesthesia) were collected.   
 
     Three and six monthly fasting blood samples were collected by the same 
pathology service and transferred to a dedicated gastrointestinal research lab 
for processing and storage. 
Blood tests included; fasting blood glucose levels, HbA1C, lipid profile 
full blood count, liver and renal function tests, zinc, copper, iron, vitamin B12, 
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folate and calcium (processed in the hospital pathology lab).  Levels of C-
peptide, ghrelin, GIP, GLP-1, glucagon, insulin, leptin, PAI-1, resistin and 
visfatin were performed using a Bio-Rad Human Diabetes Bioplex panel with 
analysis undertaken at the Australian Proteome Analysis Facility (Macquarie 
University) using a Bio-Plex 200 instrument (both from Bio-Rad, Hercules, CA, 
USA).  
NEFA were measured in plasma using reagents from Wako Diagnostics 
(Richmond, VA, USA). These were supervised by an experienced laboratory 
scientist. 
 
For bio-assays, 20 mL whole blood was collected and divided between two 
EDTA tubes.  It was stored on ice until transfer to the laboratory as a de-
identified sample with lab specific code. The blood was centrifuged and plasma 
removed for assay.  In the bariatric group, circulating biomarker levels 
immediately pre-operatively and at three and six months after surgery were 
quantified. These same markers were measured in the plasma samples of 
patients in the control group - considered to represent a ‘lean normal value’.   
 
The units are mM for NEFA and all hormone levels are in pg/mL. 
 
# Note visfatin due to analyte availability difficulties was not measured in all 
SG patients at three and six months. 
 
     Follow up continued until February 2014. 
 
Data analysis/ Statistical Methods: 
Paired t-tests were used to compare study factors pre and post surgery at time 
intervals three and six months post SG.  
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Independent (unpaired) sample t-tests were used to compare anthropometric 
results such as BMI and hormone levels between control and SG patients prior 
to  surgery. All tests were two tailed with a significance level of p=0.05. 
 
Statistical analysis to compare baseline patient characteristics of SG patients 
completing biochemical follow up (blood sampling) and their counterparts who 
did not were made, to determine whether patients lost to follow up were  
similar to those completing the study. 
     Data was analysed using Excel and GraphPad Prism Statistical Analysis 
software. 
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VIII. RESULTS: 
A] Clinical Data: 
     Clinical data were available on 16 (100%) of consenting patients at three 
months and 13 (81.3%) of patients at six months. One patient having moved 
interstate; a set of clinical notes being misplaced and a third patient being lost to 
follow up. 
 A biochemical profile of 11 (68.8%) patients at 3 months and 4 (25%) of patients 
at 6 months was obtained. 
 
     The baseline characteristics of SG cohort and control patients are 
summarized in Table 1. SG cohort and controls were age and sex matched.  
 
Table 1: Baseline demographics of SG cohort and controls who went on to have 
hormone tests.  
 
 SG cohort (N=13) Control (N=26) P value (0.05) 
Age  - Range (years) 
         - Mean (SD) 
29-71 
52 +/- 12.7SD 
27-66 
51.5+/-11.9SD 
0.99  
Sex  -  M 
         -  F 
7         
6  
14 
12 
1 
Weight (kg) (All) 
 
119.7 +/-8.4 SEM  74.3+/-2.4SEM P<0.0001 
Ideal Body Weight (kg) 70 +/-8 SD N/A as controls were 
within normal weights 
 
BMI  - Range (kg/m2) 
    
         - Mean (+/- SEM) 
32.5 to 55 
 
42.5  +/-1.8  
18.5 to 25.5 
 
23.5 +/- 0.5 
 
 
P<0.0001 
Weight (kg) 
 
Male 
133.9 +/-
10.16 SEM 
Female 
102.7 +/-
8.07 SEM 
 P<0.03 
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Serial assessment of obesity related co-morbidities was conducted at clinical 
review three and six months following surgery. The results are as summarized 
in Table 2. 
 
Table 2: Obesity related co-morbidities over time, SG cohort (N =13) 
 
^ Resolution as defined by an HbA1C <6.0% and or random blood glucose recordings <7mmol/L  
Condition 
and number 
(x) of  SG 
patients 
affected at 
time 0 
Improvement  
at 3months 
 
Resolution 
(^) at 3 
months 
Improvement 
at 6 months 
Complete resolution at 6 
months 
Diabetic (4) 
- 4 on oral 
hypoglycaemic agents 
(OHG) 
 
 
- 
 
4 off OHG 
 
- 
 
4 ceased OHG 
Hypertension (6)  
(BP >140/90) 
- 1 - 2 
Obstructive Sleep 
Apnoea (OSA) (7) 
-6 requiring CPAP 
1 - 3 1 
Gastroesophageal 
reflux (GORD)(6) 
- 1 1 1 
Osteoarthritis (6) 1   1 
Hypercholesterolaemia 
(3) 
(Total cholesterol 
>5.5mmol/L & meeting 
statin guidelines)) 
   1 
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B] BMI and Weight Data: 
The following graphs depict  
- BMI of case and control patients at baseline. 
- BMI, weight and percentage of excess body weight loss in the sleeve 
gastrectomy patients over time 
- A subgroup analysis for weight loss and gender was also performed 
 
Figure 2. SG cohort vs. control BMI: 
 
 
Unpaired t test:  
  P value P<0.0001 (p<0.05) 
Two-tailed 
  t, df t=13.38 df=37 
  
Magnitude of difference  
  Mean ± SEM of column A 23.42 ± 0.4831 N=26    
***P<0.0001 
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  Mean ± SEM of column B      42.52 ± 1.794 N=13 
  Difference between means -19.11 ± 1.428 
  95% confidence interval -22.00 to -16.21 
  R squared 0.8287 
 
 
Figure 3a. SG patient’s BMI over time (0, 3, 6, months) 
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Figure 3b. SG Patient’s Weight (kg) over time (0,3,6 months)  
 
 
 
Figure 3c. SG patient’s %EBWL at 3 and 6 months 
 
  
Column A %EBWL  at 3 months vs. Column B   % EBWL at 6 months 
  
Paired t test: 
  P value 0.0002 (p<0.05) 
   
Two tailed 
  t, df t=5.632 df=10 
***P<0.0002 
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  Number of pairs 11 
  
Magnitude of difference?  
  Mean of differences -9.636 
  95% confidence interval -13.45 to -5.824 
  R squared 0.7603 
 
Figure 3d. Baseline weight (kg)  and Gender 
 
 
 
Column A male weight (kg)  vs. Column B female weight (kg) 
  
Unpaired t test:  
  P value 0.0373 (p< 0.05) 
 Two-tailed 
  t, df t=2.401 df=10 
  
Magnitude of difference?  
  Mean ± SEM of column A 133.9 ± 10.16 N=6 
  Mean ± SEM of column B 102.7 ± 8.076 N=6 
  Difference between means 31.17 ± 12.98 
  95% confidence interval 2.245 to 60.09 
  R squared 0.3657 
 
 
 
 
P<0.03 
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C] Hormone/Biomarker Levels: 
     For each of the following hormones, SG patient plasma levels were analysed 
at zero, three and six months following surgery.   
i)  NEFA                                
ii)   C-peptide     
iii)   Ghrelin                                   
iv)   GIP                                          
v)   GLP-1                                     
vi)  Glucagon     
vii)  Insulin 
viii) Leptin 
ix)  PAI-1 
x)  Resistin 
xi)  Visfatin 
xii)  Fasting blood glucose 
 
 
 
 
 
 
 
 
 
30 
 
i) NEFA: 
There was no statistically significant difference in NEFA levels between SG 
patients at baseline to controls p<0.65 
There was a statistically significant difference in NEFA levels in SG patients 
from baseline to 3 months p<0.0038 (p< 0.05).  There was a statistically 
significant difference in NEFA levels in SG patients from baseline to 6 months 
p<0.03 (p<0.05) 
Figure 4. NEFA Assays: baseline vs. 3 months (N=13, 11) vs. 6 months ( N=4) 
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P<0.0038 
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ii) C-peptide:  
Levels were not statistically significant between controls and baseline SG 
patients (p<0.71) 
There was no statistically significant change in C-peptide level in SG patients 
from baseline to 3 months( p<0.75),  (p<0.05) 
Nor was there a statistically significant change in these hormone levels in SG 
patients from 3 to 6 months (p<0.97) 
     Magnitude of difference: 
Mean of differences -22.18 SD of differences 217.9 SEM of differences 65.70 95% 
CI      -168.6 to 124.2 
 
iii) Ghrelin: 
There was a highly statistically significant difference in baseline Ghrelin levels 
of SG patients compared to controls  p<0.0001 (p<0.05) 
There was a highly statistically significant difference in ghrelin levels measured 
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in  SG patients from baseline to 3 months p<0.0001 (p<0.05) 
There was a statistically significant difference in SG patients from baseline to 3 
months and to 6 months (one way ANOVA) p<0.04 (p<0.05) 
 
 
 
 
 
Figure 5. Ghrelin Assays - Baseline vs. 3 months (N=13, 11) vs. 6 months (N=4) 
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Magnitude of difference: 
Mean of differences -109.9  
SD of differences 51.53 
 SEM of differences 16.30   
95% CI      -146.8 to -73.08  
R squared  0.8349  
 
iv) GIP: 
There was no statistically significant difference in GIP values in SG patients at 
baseline from levels measured in matched controls  p<0.059 (p<0.05) 
There was no statistically significant difference in GIP values in SG patients 
from baseline to 3 months p<0.61 (p<0.05) 
Magnitude of difference: 
Mean of differences 17.58  
SD of differences 109.5  
SEM of differences 33.02  
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95% CI      -55.98 to 91.15  
R squared  0.02758 
 
 There was no statistically significant difference in GIP values in SG patients 
from baseline to 3 months and to 6 months (ANOVA) p<0.36 (p<0.05) 
 
v) GLP-1: 
There was no statistically significant difference in GLP-1 levels between 
baseline SG patients and controls.  P< 0.31 (p<0.05) 
There was a statistically significant difference in GLP-1 levels in SG patients 
from baseline to 3 months p<0.05 (p<0.05) 
 
Figure 6. GLP-1 Assays. Baseline vs. 3 months ( N= 13, 11) 
SG Patients GLP-1
Baseline 3 months
200
300
400
500
600
 
Number of values
Minimum
25% Percentile
Median
75% Percentile
Maximum
Mean
Std. Deviation
Std. Error
Lower 95% CI of mean
Upper 95% CI of mean
Baseline
11
266.9
314.6
338.9
363.5
497.2
346.8
58.62
17.68
307.4
386.1
3 months
11
237.0
255.4
269.7
352.1
408.6
302.2
62.54
18.86
260.2
344.2
*
* p < 0.05
[G
L
P
-1
];
 p
g
/m
l
 
Magnitude of difference: 
Mean of differences 346.8  
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SD of differences 58.62  
SEM of differences 17.68  
95% CI  307.4 to 386.1 at baseline.   
Mean of the differences at 3 months 302.2  
SD 62.5  
SEM18.86  
CI 260 to 344.2 
 There was no statistically significant difference in GLP-1 levels of SG patients 
from baseline to 3months to 6 months p<0.66 (p<0.05) ANOVA 
 
vi) Glucagon: 
There was no statistically significant difference in glucagon levels in SG patients 
from baseline compared to controls  p<0.77(p<0.05) 
There was a statistically significant difference in glucagon levels in SG patients 
from baseline to 3 months p<0.0061(p<0.05) 
 
Figure 7. Glucagon Assays. Baseline vs. 3 months ( N=13, 11) 
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Magnitude of difference: 
Mean of differences -39.18  
SD of differences 37.51  
SEM of differences 11.31  
95% CI      -64.38 to -13.98  
R squared 0.5455 
 
There was no statistically significant difference in glucagon levels in SG patients 
from 0 to 6 months p<0.28(p<0.05) 
 
vii) Insulin: 
There was a no statistically significant difference in insulin levels in SG patients 
and their controls at baseline. P<0.07 (p<0.05) 
There was a no statistically significant difference in insulin levels in SG patients 
from baseline to 3 months p<0.12 (p<0.05) 
 
Magnitude of difference: 
Mean of differences -94.33  
SD of differences 186.0  
SEM of differences 56.09  
95% CI      -219.3 to 30.64 
There was a no statistically significant difference in insulin levels in SG patients 
from baseline to 6 months p<0.76 ANOVA (p<0.05) or paired t test 0 and 6 
months p<0.5 (p<0.05) 
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viii) Leptin: 
There was no statistically significant difference in leptin levels in SG patients 
from controls at baseline p<0.10 (p<0.05) 
There was a statistically significant difference in leptin levels in SG patients 
from baseline to 3 months p<0.02 (p<0.05) 
There was no statistically significant difference in leptin levels in SG patients 
from baseline to 6 months p<0.09 (p<0.05) 
 
 
 
Figure 8. Leptin Assays. Baseline vs. 3 months (N=13, 11) 
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Magnitude of difference: 
Mean of differences -662.9  
SD of differences 756.3  
SEM of differences 239.2  
95% CI      -1204 to -121.9 
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ix) PAI-1 : 
There was no statistically significant difference in PAI levels in SG patients from 
controls at  baseline  p<0.28 (p<0.05) 
 
There was a statistically significant difference in PAI levels in SG patients from 
baseline to 3 months p<0.0073 (p<0.05) 
 
 
Figure 9. PAI Assays. Baseline vs. 3 months (N= 13, 11) 
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Magnitude of difference: 
Mean of differences -177.6  
SD of differences 175.4  
SEM of differences 52.88  
95% CI      -295.4 to -59.78 
There was no statistically significant difference in PAI levels in SG patients from 
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baseline to 6 months p<0.17 (p<0.05) ANOVA 
 
x) Resistin: 
There was a statistically significant difference in resistin levels in SG patients 
from controls at baseline p<0.05 (P<0.05)  
There was no statistically significant difference in resistin levels in SG patients 
from baseline to 3 months p<0.1332(p<0.05) 
There was no statistically significant difference in resistin levels in SG patients 
from baseline to 6 months p<0.57 (p<0.05)  
Figure 10. Resistin Assays. Baseline vs Controls ( N= 13, 26) 
 
Magnitude of difference: 
Mean of differences -305.8  
SD of differences 586.0  
SEM of differences 185.3  
95% CI crosses 1 
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xi) Visfatin :  
Note -  although planned,  analysis was not able to be performed on the 
platform due to lack of analyte availability in the lab at time 3 and 6 months, 
however baseline values were possible for all subjects and controls. 
There was a statistically significant difference in visfatin levels in SG patients 
versus controls at baseline . 
 
 
 
Figure 11. Visfatin Assays. Baseline SG vs Controls ( N= 13, 26) 
 
 
xii) Fasting blood glucose levels: 
   Four patients in our sleeve gastrectomy cohort were diabetic with a fasting 
blood glucose level (BGL) of greater than 7.0mmol/L. (Average BGL was 
9.12mmol/L) at baseline.  All four of these patients had resolution of their 
diabetes as indicated by a decrease in fasting blood glucose level to within the 
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normal range ( <7.0mmol/L) with a new average fasting BGL in this group of 
5.04mmol/L. (Definition of diabetes as per Diabetes Australia Guidelines). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood Glucose Levels over time
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Figure 12- Blood Glucose levels over time (N = 13, 11, 4 at 0, 3, 6 months) 
 
 
 
42 
IX. CONCLUSIONS: 
 
     There was a statistically significant difference between the SG patient’s 
baseline anthropometric characteristics of weight and BMI, confirming that in 
this respect the cohorts were different from each other.  Age and gender p 
values approached 1 between the SG cohort and controls, indicating good 
matching, with no difference between the groups.  Males in the SG cohort were 
significantly heavier at baseline than females undergoing SG.  
 
Our primary outcome measures were percentage excess body weight lost 
at 3 and 6 months post-operatively and change in hormone profiles. 
Percentage excess body weight lost  (%EBWL) at three months had a 
mean of 42.3% +/- 8.4 SD.  Percentage of excess body weight lost at six months 
had a mean of 51.5% +/- 18.5 SD of total EBWL.  There was a statistically 
significant (p<0.05) incremental weight loss between three and six month time 
points from baseline, p<0.0001 and p<0.0009 respectively. 
  There was a statistically significant (p<0.05) incremental weight loss from 
baseline and 3 months (p<0.0001) and between 3 and 6 month time points 
(p<0.0009). 
 
A statistically significant (p<0.05) reduction in levels of NEFA, ghrelin, 
GLP-1, glucagon, leptin and PAI-1 were seen in subjects between baseline and 3 
month post-operative plasma assays. 
 
No statistically significant association was determined in the hormone 
levels of   C-peptide, GIP, insulin or resistin in SG subjects at baseline and three 
months post surgery. 
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     There was a statistically significant (p<0.05) reduction in levels of NEFA and 
ghrelin at 6 months.   
     However due to small sample numbers at 6 months it is unclear if a further 
change in these hormone levels in subjects at 6 months compared to 3 months 
occurs. 
     A baseline difference between plasma hormone levels in subjects and 
controls a time 0 was only evident for resistin and visfatin.   
Table 3: Hormone level changes in SG patients at baseline vs. 3 months post SG 
Hormone Change baseline to 3 
months 
Significant  
Y – Yes,  N-No  
 
(p<0.05 is significant) 
NEFA Decrease Y  P<0.0038 
Ghrelin Decrease Y P<0.0001 
GLP-1 Decrease Y P<0.05 
Glucagon Decrease Y P<0.0061 
Leptin 
 
Decrease Y 
 
P<0.02 
PA1 Decrease Y P<0.0073 
C-peptide  N P<0.75 
GIP  N P<0.61 
Insulin  N P<0.12 
Resistin  N P<0.1332 
Visfatin  Not available   
 
There was no difference in the characteristics of the patients who completed 
clinical and biochemical follow up versus those who had clinical follow up 
alone.   
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X. DISCUSSION: 
Obesity is a major health challenge with bariatric surgery being increasingly 
relied on to enable weight loss. In Australia, Medicare Benefits Schedule (MBS) 
item numbers reflect this. Total bariatric operations performed have increased 
from 6,557 in 2005-6 to 13,600 in 2009-10. (4) 
Figure 4: 
 
The table above is taken from a report by the Australian Department of Health 
and Ageing to assess economic impact of obesity, given 17.5% of the population 
were obese in the 2008 Australian census.  From 2005-2010, spending on 
bariatric surgery has more than tripled to $19.3 million in 2009). This figure still 
pales in comparison to the cost of treating long term complications of obesity; 
diabetes, cardiovascular disease, cancer, osteoarthritis and decreased 
productivity which was estimated to be $8.3 billion in 2008. (4) 
 
LAGB and RYGB have been well studied and good knowledge exists as to their 
mechanism of inducing weight loss.  
LAGB  relies on  volume restriction to promote early satiety and a decrease in 
caloric intake. The advantages of this operation include relative ease of 
   ADoHA 
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placement with short operating time, fast recovery and return to normal 
activities. It relies on behavioural modification and ‘sensible food choices’ as 
well as adequate exercise for maximum benefit. Weight loss following LAGB is 
slower and lower than other forms of bariatric surgery. Generally 1kg/week 
resulting in 40-50% EBWL at 18 months is described. (25) 
RYGB was first described by Mason and Ito in 1966 and has become the most 
commonly performed bariatric operation in the USA. The creation of a small 
gastric pouch, a gastrojejunostomy and a Roux limb of variable length cause 
volume restriction and a malabsorption syndrome.  The hormonal mechanisms 
of weight loss are indicated in the diagram below.  
Figure 13: 
 
 
The mechanisms of weight loss in RYGB surgery. Surg Clin N Am 91 (2011) 1149-1161. 
Physiology of weight loss surgery. Park C, Torquati A.  
60-75% EBW is lost in the 18-24 months following RYGB  (25). Vitamin and 
mineral deficiencies, anastomotic leak or stricture, dumping syndrome 
(diarrhea, abdominal pain, diaphoresis and pre-syncope that occur following 
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high sugar intake) are the disadvantages to this procedure. (25) The resolution 
of comorbidities including the amelioration of diabetes and improvements in 
insulin resistance and glucose tolerance is well established. Bypassing the 
antrum, duodenum, and jejunum during RYGB may provide additional 
benefits in the treatment of diabetes by altering gut signaling mechanisms that 
are beneficial to treating insulin resistance or glucose tolerance when compared 
with restrictive operations alone (26) 
Sleeve gastrectomy surgery is currently considered the ‘happy medium’ 
between LAGB and RYGB with notable improvements in BMI and metabolic 
parameters post operatively.  Stapled resection of the greater curvature of the 
stomach results in volume reduction and series of metabolic feedback responses 
which are currently the topic of investigation. It is a technically easier operation 
than RYGB with the advantage of maintained intestinal continuity so 
preventing nutritional deficiencies. Disadvantages include staple line bleed, 
leak or stricture. (25) 
Molecular/Hormonal changes known to occur post SG include: 
- decrease in ghrelin levels 
- rapid nutrient transit into the distal bowel mediated by peptide YY and 
GLP-1 (27) 
- Other hormonal mechanism yet to be established including alterations in 
bile acid binding and interaction with gut flora. 
Our study has confirmed rapid and durable weight loss as characterized by 
percentage excess body weight lost (%EBWL) at 3 and 6 months post sleeve 
gastrectomy surgery. 
The mean %EBW loss was 42.3% +/- 8.4SD at 3 months and 51.5% +/- 18.5SD at 6 
months. There was a statistically significant incremental weight loss between 3 
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and 6 month time points from baseline, p < 0.0001 and p < 0.0009 respectively. 
This compares favourably to other studies for example a meta-analysis by Shi et 
al in Obesity Surgery 2010 demonstrates  a EBWL of 35% at 6 months. (24) 
 
A number of hormonal changes were observed in these patients ( Table 3 of 
results). Of statistical significance are a fall in ghrelin, GLP-1, glucagon, PAI-1 
and leptin at 3 months.  A continued significant drop at 6 months was observed 
for ghrelin. 
     The literature to date demonstrates largely conflicting data for the hormonal 
changes following sleeve gastrectomy surgery.  Our study adds to the body of 
evidence already available on what hormonal changes are most likely to 
predominate in subjects following this procedure.  The majority of studies are 
of small sample size and  it may prove insightful to undertake a meta-analysis 
to determine what the overall trend is. 
     Other effects of gastric sleeve surgery include increased resolution of obesity 
related co-morbidites, such as obstructive sleep apnoea and T2DM.  This is in 
keeping with other studies. 
     Successful management of obesity requires safe, effective, long term 
treatments that resist the compensatory mechanisms of the body to desire to 
store food.  Bariatric surgery in the form of  sleeve gastrectomy has been shown 
to be very successful in this (9).   
    A strength of our study is that it also demonstrates in SG specifically the 
hormone profile of changes that induce more then a mere mechanical 
component to weight loss. 
     This study confirms and adds to the literature on the success of SG surgery 
in achieving and maintaining profound weight loss for obese patients. To date 
there is no equivalent medical pharmacotherapy to achieve such success for  
 
 
48 
these patients. Sleeve gastrectomy offers a more effective weight loss strategy 
than LAGB and carries less surgical risk and nutritional disruption than RYGB. 
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XI. LIMITATIONS: 
      
There are several limitations of this study.  
i) Timing for patients and follow up: 
Our attrition rate was high, not uncommon for studies of long term weight loss. 
The possibility that the changes in hormone levels differed in patients who 
discontinued the study can not be excluded.  As part of this attrition rate, in 
terms of timing of the study, our time line of data collection was limited As 
such,  there is a need for longitudinal data in this cohort, which would add to 
the literature base and experience in SG patient studies.     
 
ii)  Multiplex bioassay platform: 
The use of a multiplex bioassay platform results in measurements of individual 
hormones that are less accurate and precise than those obtained with an 
individualized optimized assay.  However, this is likely to minimise the 
detection of changes occurring post SG with weight loss and serve to minimise 
the attributable detection of change.   
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XII. FUTURE DIRECTIONS: 
 
     Circulating hormonal mediators of regulation of body weight are altered 
significantly in a number of instances but do not revert to pre-surgical levels of 
‘normal’ at three or six months post operatively.  Further future research work 
in our cohort and others, could involve investigating  additional markers, such 
as acylated ghrelin and  high and low molecular weight forms of adiponectin.  
FXR and other bile acid pathway metabolites would also be interesting to study.  
Longitudinal data in our SG cohort out to 12 months and beyond would also be 
interesting to document anthropometric and hormonal changes.   
 
     To date, bariatric surgery with SG as the technique of choice. Having a low 
morbidity and mortality, it  represents the most efficient and durable mode of 
weight loss for the ever increasing number of morbidly obese patients.  Our 
results confirm quick and sustained weight loss that correlates to a change in 
profile of a variety of hormones that are known to be associated with weight 
gain/loss.  It suggests a number of potential hormonal pathways for 
pharmacological targets.  Our research adds to the literature to encourage 
further research to evaluate if a primary hormonal defect can be found to be 
responsible for promoting weight gain and so its counter could promote weight 
loss.   It may be feasible in the long term to exploit this physicochemical 
imbalance and develop a pharmacological means of achieving swift and 
sustained weight loss without the risks of surgery.   
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